Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.60 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.39 |
| ▸ | USP2 | O75604 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074023 | 0.95 | ALK (0.66) | ALKHIF1ACYP1A2CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4360985 | 0.94 | ALK (0.61) | ALKP2RY12 | |
| Trifluoroacetic Acid SCHEMBL4371092 | 0.93 | ALK (0.66) | ALKP2RY12SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4360466 | 0.91 | ALK (0.61) | ALKHSD17B10SMN1; SMN2MAPK1 | |
| Trifluoroacetic Acid SCHEMBL4363168 | 0.89 | ALK (0.63) | ALKSMN1; SMN2 | |
| SCHEMBL1076850 | 0.89 | ALK (0.67) | ALK | |
| SCHEMBL1074091 | 0.88 | ALK (0.72) | ALKP2RY12 | |
| SCHEMBL1076871 | 0.88 | ALK (0.65) | ALKHSD17B10SMN1; SMN2MAPK1 | |
| Trifluoroacetic Acid SCHEMBL1074487 | 0.86 | ALK (0.63) | ALK | |
| SCHEMBL1076611 | 0.86 | ALK (0.67) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALK 3/4885P2RY12 3344/4885HIF1A 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.